Hirosumi Miyakawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hirosumi Miyakawa has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Mizuki Ogawa
Laboratory of Veterinary Internal Medicine II, School of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan
6 shared publications Naoyuki Takemura
Laboratory of Veterinary Internal Medicine II, School of Veterinary Medicine, Nippon Veterinary and Life Science University, Musashino-shi, Tokyo, Japan
5 shared publicationsYuichi Miyagawa
Laboratory of Veterinary Internal Medicine II, School of Veterinary Medicine, Nippon Veterinary and Life Science University, Musashino-shi, Tokyo, Japan
5 shared publicationsHuai-Hsun Hsu
Laboratory of Veterinary Internal Medicine II, Nippon Veterinary and Life Science University, 1-7-1 Kyonan, Musashino, Tokyo 180-0023, Japan
3 shared publications- Huai-Hsun Hsu
Laboratory of Veterinary Internal Medicine II, School of Veterinary Medicine, Nippon Veterinary and Life Science University, Musashino-shi, Japan
3 shared publications - Yuichi Miyagawa
Laboratory of Veterinary Internal Medicine II Nippon Veterinary and Life Science University Tokyo Japan
3 shared publications
Latest Publications
- 2 September 2026
- Published by Wiley in Journal of Small Animal Practice
Clinical findings and outcomes of juvenile‐onset chronic kidney disease of unknown aetiology in dogs: a retrospective study of 36 cases (2010‐2023)
Objectives: To describe the clinical findings and outcomes of juvenile‐onset chronic kidney disease of unknown aetiology in dogs. Materials and Methods: This retrospective study included 36 client‐owned dogs under 3 years of age with chronic kidney disease. In the observational cohort study, the signalment and clinicopathology findings in the dogs ( n = 36) were described. A longitudinal analysis ( n = 28) was performed to investigate the time to chronic kidney disease progression and death. The risk of chronic kidney disease progression defined as increased >25% of serum creatinine concentration was calculated using the Cox proportional hazard model. Results: The most common breeds were Labrador retrievers and Shetland sheepdogs ( n = 5, respectively). Seven dogs were classified as chronic kidney disease stage 1, 17 as stage 2, eight as stage 3 and four as stage 4 according to International Renal Interest Society guidelines. The prevalence of proteinuria (urine protein:creatinine ratio ≥ 0.5) was 35%. None of the dogs had an indirect systolic blood pressure ≥ 160 mmHg. Serum total calcium concentration at presentation was positively associated with the risk for chronic kidney disease progression (hazard ratio, 2.24; 95% confidence interval, 1.11 to 4.53; P = .03). All dogs with chronic kidney disease stage 3 experienced progression to stage 4. Overall, the median survival time (95% confidence interval) was 1461 days (530 to 2620 days). Clinical Significance: Juvenile‐onset chronic kidney disease of unknown aetiology was diagnosed in the various breeds of dogs. The prevalence of hypertension was lower than reported in previous studies. Serum total calcium concentration at presentation was associated with the risk of chronic kidney disease progression. Our study provides useful information on the characteristics and outcomes of canine juvenile‐onset chronic kidney disease.
- 2 September 2026
- Published by Wiley in Journal of Small Animal Practice
Clinical findings and outcomes of juvenile‐onset chronic kidney disease of unknown aetiology in dogs: a retrospective study of 36 cases (2010‐2023)
Objectives: To describe the clinical findings and outcomes of juvenile‐onset chronic kidney disease of unknown aetiology in dogs. Materials and Methods: This retrospective study included 36 client‐owned dogs under 3 years of age with chronic kidney disease. In the observational cohort study, the signalment and clinicopathology findings in the dogs ( n = 36) were described. A longitudinal analysis ( n = 28) was performed to investigate the time to chronic kidney disease progression and death. The risk of chronic kidney disease progression defined as increased >25% of serum creatinine concentration was calculated using the Cox proportional hazard model. Results: The most common breeds were Labrador retrievers and Shetland sheepdogs ( n = 5, respectively). Seven dogs were classified as chronic kidney disease stage 1, 17 as stage 2, eight as stage 3 and four as stage 4 according to International Renal Interest Society guidelines. The prevalence of proteinuria (urine protein:creatinine ratio ≥ 0.5) was 35%. None of the dogs had an indirect systolic blood pressure ≥ 160 mmHg. Serum total calcium concentration at presentation was positively associated with the risk for chronic kidney disease progression (hazard ratio, 2.24; 95% confidence interval, 1.11 to 4.53; P = .03). All dogs with chronic kidney disease stage 3 experienced progression to stage 4. Overall, the median survival time (95% confidence interval) was 1461 days (530 to 2620 days). Clinical Significance: Juvenile‐onset chronic kidney disease of unknown aetiology was diagnosed in the various breeds of dogs. The prevalence of hypertension was lower than reported in previous studies. Serum total calcium concentration at presentation was associated with the risk of chronic kidney disease progression. Our study provides useful information on the characteristics and outcomes of canine juvenile‐onset chronic kidney disease.
- Open Access
- 27 August 2022
- Published by Veterinary World in Veterinary World
- Vol. 15 (8) , 2072-2083
Evaluation of the association between electrocardiogram parameters and left cardiac remodeling in dogs with myxomatous mitral valve disease
Background and Aim: Electrocardiography (ECG) is an adjunct for cardiac enlargement diagnosis. However, its efficacy in assessing left cardiac remodeling (left atrial and left ventricular enlargement) in dogs with myxomatous mitral valve disease (MMVD) remains unclear. This study aimed to evaluate the association between ECG parameters and left cardiac remodeling and to investigate whether the rate of change in ECG waveforms in the same individual reflected left cardiac remodeling in dogs with MMVD. Materials and Methods: This retrospective study included 20 healthy dogs and 140 dogs with MMVD. Data on clinical variables were obtained through physical examination, thoracic radiography, and echocardiography. The ECG parameters were the P-wave duration, PR interval, QRS complex duration, P-wave amplitude, R-wave amplitude, and mean electrical axis. Dogs with examination data that could be obtained multiple times during the study period were classified into the non-progressive and progressive groups. Results: Only the P-wave and QRS complex durations were selected as significant variables associated with imaging test parameters (p < 0.05); they had a relatively higher discriminatory ability for the left cardiac remodeling than other ECG parameters. The rates of change in the PR interval and R-wave amplitude were significantly higher in the progressive group than in the non-progressive group. Conclusion: In dogs with MMVD, the P-wave and QRS complex durations were significantly correlated with the left cardiac remodeling indicators. Furthermore, an increased rate of change in the PR interval and R-wave amplitude in the same individual may indicate left cardiac remodeling.
- 27 August 2022
- Published by Veterinary World in Veterinary World
- Vol. 15 (8) , 2072-2083
Open AccessEvaluation of the association between electrocardiogram parameters and left cardiac remodeling in dogs with myxomatous mitral valve disease
Background and Aim: Electrocardiography (ECG) is an adjunct for cardiac enlargement diagnosis. However, its efficacy in assessing left cardiac remodeling (left atrial and left ventricular enlargement) in dogs with myxomatous mitral valve disease (MMVD) remains unclear. This study aimed to evaluate the association between ECG parameters and left cardiac remodeling and to investigate whether the rate of change in ECG waveforms in the same individual reflected left cardiac remodeling in dogs with MMVD. Materials and Methods: This retrospective study included 20 healthy dogs and 140 dogs with MMVD. Data on clinical variables were obtained through physical examination, thoracic radiography, and echocardiography. The ECG parameters were the P-wave duration, PR interval, QRS complex duration, P-wave amplitude, R-wave amplitude, and mean electrical axis. Dogs with examination data that could be obtained multiple times during the study period were classified into the non-progressive and progressive groups. Results: Only the P-wave and QRS complex durations were selected as significant variables associated with imaging test parameters (p < 0.05); they had a relatively higher discriminatory ability for the left cardiac remodeling than other ECG parameters. The rates of change in the PR interval and R-wave amplitude were significantly higher in the progressive group than in the non-progressive group. Conclusion: In dogs with MMVD, the P-wave and QRS complex durations were significantly correlated with the left cardiac remodeling indicators. Furthermore, an increased rate of change in the PR interval and R-wave amplitude in the same individual may indicate left cardiac remodeling.
- 26 April 2022
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 24 (6) , e70-e75
Upper urolithiasis in cats with chronic kidney disease: prevalence and investigation of serum and urinary calcium concentrations
Objectives: This study aimed to define the prevalence of upper urolithiasis in cats with chronic kidney disease (CKD) in a referral population, and to compare urinary calcium:creatinine ratio (UCa:Cr), and total and ionised calcium between cats with CKD with and without upper urolithiasis. Methods: The medical records of cats diagnosed with CKD were reviewed for signalment, body weight, diet and prevalence of upper urolithiasis. Cats with preserved urine samples were further classified into two groups: urolithiasis group (upper urolithiasis identified by abdominal ultrasonography) and control group (CKD of unknown origin). Serum biochemical analysis, CKD stage, blood gas analysis, urine specific gravity and UCa:Cr were compared between groups using a two-sample t-test or Mann–Whitney U-test for continuous variable and a χ2 test or Fisher’s exact test for categorical variables. Multivariable binary logistic regression analysis was used to identify risk factors. Results: Among the 140 cats with CKD, the prevalence of upper urolithiasis was 73%. Fifty cats (5, 29 and 16 cats with CKD stages 1, 2 and 3, respectively) with urine samples met the inclusion criteria and were included in the analysis. Among cats with CKD, being purebred (odds ratio [OR] = 81.56; P = 0.03) and being fed dry food only (OR = 25.06; P = 0.001) were identified as independent upper urolithiasis risk factors; those with upper urolithiasis were more likely to be exclusively fed with urine-acidifying food ( P <0.001) and have increased serum ionised calcium (iCa) ( P = 0.044), fractional excretion of calcium ( P = 0.45) and UCa:Cr ( P = 0.005) than cats with CKD without upper urolithiasis. Conclusions and relevance: Cats with CKD that were purebred, fed dry food and fed urine-acidifying food only often had upper urolithiasis. A higher UCa:Cr may be a result of increased serum iCa and may cause upper urolithiasis.
- 26 April 2022
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 24 (6) , e70-e75
Upper urolithiasis in cats with chronic kidney disease: prevalence and investigation of serum and urinary calcium concentrations
Objectives: This study aimed to define the prevalence of upper urolithiasis in cats with chronic kidney disease (CKD) in a referral population, and to compare urinary calcium:creatinine ratio (UCa:Cr), and total and ionised calcium between cats with CKD with and without upper urolithiasis. Methods: The medical records of cats diagnosed with CKD were reviewed for signalment, body weight, diet and prevalence of upper urolithiasis. Cats with preserved urine samples were further classified into two groups: urolithiasis group (upper urolithiasis identified by abdominal ultrasonography) and control group (CKD of unknown origin). Serum biochemical analysis, CKD stage, blood gas analysis, urine specific gravity and UCa:Cr were compared between groups using a two-sample t-test or Mann–Whitney U-test for continuous variable and a χ2 test or Fisher’s exact test for categorical variables. Multivariable binary logistic regression analysis was used to identify risk factors. Results: Among the 140 cats with CKD, the prevalence of upper urolithiasis was 73%. Fifty cats (5, 29 and 16 cats with CKD stages 1, 2 and 3, respectively) with urine samples met the inclusion criteria and were included in the analysis. Among cats with CKD, being purebred (odds ratio [OR] = 81.56; P = 0.03) and being fed dry food only (OR = 25.06; P = 0.001) were identified as independent upper urolithiasis risk factors; those with upper urolithiasis were more likely to be exclusively fed with urine-acidifying food ( P <0.001) and have increased serum ionised calcium (iCa) ( P = 0.044), fractional excretion of calcium ( P = 0.45) and UCa:Cr ( P = 0.005) than cats with CKD without upper urolithiasis. Conclusions and relevance: Cats with CKD that were purebred, fed dry food and fed urine-acidifying food only often had upper urolithiasis. A higher UCa:Cr may be a result of increased serum iCa and may cause upper urolithiasis.
- 8 February 2022
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 24 (12) , 1245-1252
Association between serum fibroblast growth factor-23 concentrations and blood calcium levels in chronic kidney disease cats with upper urolithiasis
Objectives: This study investigated whether serum fibroblast growth factor (FGF)-23 concentrations are associated with serum total calcium (tCa) and blood ionised calcium (iCa) concentrations in cats with chronic kidney disease (CKD) and upper urolithiasis. Methods: Serum samples and the medical records of cats with CKD with nephroliths, ureteroliths or both were investigated retrospectively. Cats with a serum creatinine concentration >250 μmol/l and/or a serum phosphorus concentration ⩾1.50 mmol/l were excluded. Based on cut-offs for serum tCa (2.70 mmol/l) or blood iCa (1.40 mmol/l), cats were divided into the following groups: total hypercalcaemia (H-tCa) (>2.70 mmol/l) and total normocalcaemia (N-tCa) (⩽2.70 mmol/l) groups, or ionised hypercalcaemia (H-iCa) (>1.40 mmol/l) and ionised normocalcaemia (N-iCa) (⩽1.40 mmol/l) groups, respectively. Serum FGF-23 concentrations were compared between groups and correlation analysis was performed. Results: Thirty-two cats with CKD and upper urolithiasis were included. Serum FGF-23 concentrations in the H-tCa group (median 573 pg/ml [range 125–3888]; n = 12) were significantly higher compared with the N-tCa group (median 245 pg/ml [range 94–627]; n = 20) ( P = 0.001). Serum FGF-23 concentrations in the H-iCa group (median 1479 pg/ml [range 509–3888]; n = 6) increased significantly compared with the N-iCa group (median 245 pg/ml [range 94–637]; n = 26) ( P r = 0.511, P = 0.003) and blood iCa concentrations ( r = 0.425, P = 0.015) but not serum creatinine ( r = 0.279, P = 0.122) or phosphorus concentrations ( r = 0.208, P = 0.253). Conclusions and relevance Increased serum FGF-23 concentrations were associated with hypercalcaemia independently of creatinine and phosphate status in cats with CKD and upper urolithiasis.
- 8 February 2022
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 24 (12) , 1245-1252
Association between serum fibroblast growth factor-23 concentrations and blood calcium levels in chronic kidney disease cats with upper urolithiasis
Objectives: This study investigated whether serum fibroblast growth factor (FGF)-23 concentrations are associated with serum total calcium (tCa) and blood ionised calcium (iCa) concentrations in cats with chronic kidney disease (CKD) and upper urolithiasis. Methods: Serum samples and the medical records of cats with CKD with nephroliths, ureteroliths or both were investigated retrospectively. Cats with a serum creatinine concentration >250 μmol/l and/or a serum phosphorus concentration ⩾1.50 mmol/l were excluded. Based on cut-offs for serum tCa (2.70 mmol/l) or blood iCa (1.40 mmol/l), cats were divided into the following groups: total hypercalcaemia (H-tCa) (>2.70 mmol/l) and total normocalcaemia (N-tCa) (⩽2.70 mmol/l) groups, or ionised hypercalcaemia (H-iCa) (>1.40 mmol/l) and ionised normocalcaemia (N-iCa) (⩽1.40 mmol/l) groups, respectively. Serum FGF-23 concentrations were compared between groups and correlation analysis was performed. Results: Thirty-two cats with CKD and upper urolithiasis were included. Serum FGF-23 concentrations in the H-tCa group (median 573 pg/ml [range 125–3888]; n = 12) were significantly higher compared with the N-tCa group (median 245 pg/ml [range 94–627]; n = 20) ( P = 0.001). Serum FGF-23 concentrations in the H-iCa group (median 1479 pg/ml [range 509–3888]; n = 6) increased significantly compared with the N-iCa group (median 245 pg/ml [range 94–637]; n = 26) ( P r = 0.511, P = 0.003) and blood iCa concentrations ( r = 0.425, P = 0.015) but not serum creatinine ( r = 0.279, P = 0.122) or phosphorus concentrations ( r = 0.208, P = 0.253). Conclusions and relevance Increased serum FGF-23 concentrations were associated with hypercalcaemia independently of creatinine and phosphate status in cats with CKD and upper urolithiasis.
- Open Access
- 1 January 2022
- Published by Japanese Society of Veterinary Science in Journal of Veterinary Medical Science
- Vol. 84 (2) , 257-260
Assessment of the measurement of canine and feline serum fibroblast growth factor-23 concentrations by automated chemiluminescence immunoassay
This study compared canine and feline fibroblast growth factor (FGF)-23 concentration measurements between automated chemiluminescence assay (CLEIA) and enzyme-linked immunosorbent assay (ELISA). Seventy serum samples each from dogs and cats were evaluated. FGF-23 measurements by CLEIA significantly correlated with those of ELISA in both dogs and cats. The Bland–Altman test showed that FGF-23 between CLEIA and ELISA had fixed and proportional biases, respectively, in both dogs and cats. Measurements by CLEIA were lower than those of ELISA, especially in higher serum FGF-23 concentrations. This study showed that FGF-23 concentrations in dogs and cats can be evaluated by automated CLEIA. However, FGF-23 cannot be directly compared between CLEIA and ELISA.
- 1 January 2022
- Published by Japanese Society of Veterinary Science in Journal of Veterinary Medical Science
- Vol. 84 (2) , 257-260
Open AccessAssessment of the measurement of canine and feline serum fibroblast growth factor-23 concentrations by automated chemiluminescence immunoassay
This study compared canine and feline fibroblast growth factor (FGF)-23 concentration measurements between automated chemiluminescence assay (CLEIA) and enzyme-linked immunosorbent assay (ELISA). Seventy serum samples each from dogs and cats were evaluated. FGF-23 measurements by CLEIA significantly correlated with those of ELISA in both dogs and cats. The Bland–Altman test showed that FGF-23 between CLEIA and ELISA had fixed and proportional biases, respectively, in both dogs and cats. Measurements by CLEIA were lower than those of ELISA, especially in higher serum FGF-23 concentrations. This study showed that FGF-23 concentrations in dogs and cats can be evaluated by automated CLEIA. However, FGF-23 cannot be directly compared between CLEIA and ELISA.
- 1 September 2021
- Published by Elsevier in Research in Veterinary Science
- Vol. 138, 11-18
Evaluation of the progression of non-azotemic proteinuric chronic kidney disease in dogs
- 1 September 2021
- Published by Elsevier in Research in Veterinary Science
- Vol. 138, 11-18
Evaluation of the progression of non-azotemic proteinuric chronic kidney disease in dogs
- 25 August 2021
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 24 (8) , 815-820
Serum fibroblast growth factor-23 concentrations in young and mature adult cats with chronic kidney disease
Objectives: The aim of this study was to investigate serum fibroblast growth factor (FGF)-23 concentrations in young and mature adult cats with chronic kidney disease (CKD). Methods: The present study retrospectively investigated the serum samples and medical records of 1–8-year-old clinically healthy cats (control group, n = 7) and cats with CKD (n = 54). Cats with CKD were divided into four stages based on serum creatinine concentrations, according to the International Renal Interest Society (IRIS) CKD guidelines. Serum FGF-23 concentrations were compared between cats in the control group, IRIS stages 1, 2 and 3–4 CKD. Continuous variables were analysed using correlations and multiple linear regression. Results: Serum FGF-23 concentrations were significantly higher in cats with IRIS stages 1, 2 and 3–4 CKD, compared with those in the control group ( P = 0.02, P = 0.002 and P = 0.002, respectively). Additionally, serum FGF-23 concentrations in cats with IRIS stages 3–4 CKD had higher serum FGF-23 concentrations than those with IRIS stages 1 and 2 CKD ( P = 0.04 and P = 0.02, respectively). In the multiple linear regression analysis, serum urea nitrogen concentration, serum phosphorus concentration and blood ionised calcium concentration were independent variables predicting serum FGF-23 concentration. Conclusions and relevance: Serum FGF-23 concentrations in younger cats with CKD increased in early-stage CKD and were associated with mineral metabolic markers, as also occurs in geriatric cats.
- 25 August 2021
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 24 (8) , 815-820
Serum fibroblast growth factor-23 concentrations in young and mature adult cats with chronic kidney disease
Objectives: The aim of this study was to investigate serum fibroblast growth factor (FGF)-23 concentrations in young and mature adult cats with chronic kidney disease (CKD). Methods: The present study retrospectively investigated the serum samples and medical records of 1–8-year-old clinically healthy cats (control group, n = 7) and cats with CKD (n = 54). Cats with CKD were divided into four stages based on serum creatinine concentrations, according to the International Renal Interest Society (IRIS) CKD guidelines. Serum FGF-23 concentrations were compared between cats in the control group, IRIS stages 1, 2 and 3–4 CKD. Continuous variables were analysed using correlations and multiple linear regression. Results: Serum FGF-23 concentrations were significantly higher in cats with IRIS stages 1, 2 and 3–4 CKD, compared with those in the control group ( P = 0.02, P = 0.002 and P = 0.002, respectively). Additionally, serum FGF-23 concentrations in cats with IRIS stages 3–4 CKD had higher serum FGF-23 concentrations than those with IRIS stages 1 and 2 CKD ( P = 0.04 and P = 0.02, respectively). In the multiple linear regression analysis, serum urea nitrogen concentration, serum phosphorus concentration and blood ionised calcium concentration were independent variables predicting serum FGF-23 concentration. Conclusions and relevance: Serum FGF-23 concentrations in younger cats with CKD increased in early-stage CKD and were associated with mineral metabolic markers, as also occurs in geriatric cats.
- Open Access
- 21 August 2021
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 35 (5) , 2296-2305
Association between serum fibroblast growth factor-23 concentration and development of hyperphosphatemia in normophosphatemic dogs with chronic kidney disease
Background Fibroblast growth factor (FGF)-23 is increased first in the sequence of changes associated with chronic kidney disease (CKD)-mineral and bone disorder. Thus, its measurement may serve as a predictive indicator of incident hyperphosphatemia. Objectives To investigate whether serum FGF-23 concentration in normophosphatemic dogs with CKD is associated with the risk of the subsequent development of hyperphosphatemia and CKD progression. Animals Forty-two normophosphatemic dogs with CKD. Methods Blood samples and medical records were retrospectively investigated. Hyperphosphatemia was defined as a serum phosphorous concentration >5.0 mg/dL. Progression was defined as a >1.5-fold increase in serum creatinine concentration. The time periods and hazard ratios for these outcomes were assessed using Kaplan-Meier analysis, log-rank test, and univariate Cox regression analysis. The variables associated with the outcomes in the univariate analysis were included in the multivariate Cox regression model with backward selection. Results Serum FGF-23 concentration >528 pg/mL was associated with a shorter time to development of hyperphosphatemia (P < .001) and CKD progression (P < .001). In multiple Cox regression analysis, increased FGF-23 concentration remained a significant variable associated with these outcomes (P < .05). Conclusions and Clinical Importance Increased FGF-23 concentration in normophosphatemic dogs with CKD was associated with significant risk of development of hyperphosphatemia, independent of CKD stage, and of the progression of CKD. Future research focusing on whether interventions that decrease FGF-23 secretion will slow the development of hyperphosphatemia and CKD progression is needed.
- 21 August 2021
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 35 (5) , 2296-2305
Open AccessAssociation between serum fibroblast growth factor-23 concentration and development of hyperphosphatemia in normophosphatemic dogs with chronic kidney disease
Background Fibroblast growth factor (FGF)-23 is increased first in the sequence of changes associated with chronic kidney disease (CKD)-mineral and bone disorder. Thus, its measurement may serve as a predictive indicator of incident hyperphosphatemia. Objectives To investigate whether serum FGF-23 concentration in normophosphatemic dogs with CKD is associated with the risk of the subsequent development of hyperphosphatemia and CKD progression. Animals Forty-two normophosphatemic dogs with CKD. Methods Blood samples and medical records were retrospectively investigated. Hyperphosphatemia was defined as a serum phosphorous concentration >5.0 mg/dL. Progression was defined as a >1.5-fold increase in serum creatinine concentration. The time periods and hazard ratios for these outcomes were assessed using Kaplan-Meier analysis, log-rank test, and univariate Cox regression analysis. The variables associated with the outcomes in the univariate analysis were included in the multivariate Cox regression model with backward selection. Results Serum FGF-23 concentration >528 pg/mL was associated with a shorter time to development of hyperphosphatemia (P < .001) and CKD progression (P < .001). In multiple Cox regression analysis, increased FGF-23 concentration remained a significant variable associated with these outcomes (P < .05). Conclusions and Clinical Importance Increased FGF-23 concentration in normophosphatemic dogs with CKD was associated with significant risk of development of hyperphosphatemia, independent of CKD stage, and of the progression of CKD. Future research focusing on whether interventions that decrease FGF-23 secretion will slow the development of hyperphosphatemia and CKD progression is needed.
- 9 October 2020
- Published by Wiley in Journal of Small Animal Practice
- Vol. 61 (12) , 744-751
Fibroblast growth factor‐23 as an early marker of CKD‐mineral bone disorder in dogs: preliminary investigation
Objectives To examine the relationship between fibroblast growth factor‐23 levels, chronic kidney disease severity and mineral metabolic disorders associated to chronic kidney disease in dogs. Materials and Methods Fifteen control and 75 chronic kidney disease dogs were retrospectively included. Serum fibroblast growth factor‐23 concentration and other phosphate metabolite parameters were compared between controls and each International Renal Interest Society stage. Multiple regression analysis was performed to determine the predictors of fibroblast growth factor‐23. Results Serum fibroblast growth factor‐23 concentrations were significantly higher in dogs with IRIS stages 2, 3 and 4 chronic kidney disease than those in dogs in control group and with stage 1 and increased along with the severity of chronic kidney disease. Compared with control dogs, serum intact parathyroid hormone significantly increased from stage 2 and serum phosphorus concentrations increased in dogs with stage 4. In dogs with stage 2, fibroblast growth factor‐23 levels significantly increased in those with hyperphosphatemia compared with those with normophosphatemia. While eight of 26 (30.8%) dogs with stage 2 developed hyperparathyroidism (intact parathyroid hormone>8.5 ng/L), 19 (73.1%) dogs with stage 2 had elevated fibroblast growth factor‐23 levels above the reference range (>528 pg/mL). Log creatinine, log intact parathyroid hormone and log product of total calcium and phosphorus were independent predictors of log fibroblast growth factor‐23. Clinical Significance This preliminary study suggests that canine fibroblast growth factor‐23 might be involved in mineral metabolic disorders associated to chronic kidney disease in dogs, and this factor could be potentially used as an early marker for this condition.
- 9 October 2020
- Published by Wiley in Journal of Small Animal Practice
- Vol. 61 (12) , 744-751
Fibroblast growth factor‐23 as an early marker of CKD‐mineral bone disorder in dogs: preliminary investigation
Objectives To examine the relationship between fibroblast growth factor‐23 levels, chronic kidney disease severity and mineral metabolic disorders associated to chronic kidney disease in dogs. Materials and Methods Fifteen control and 75 chronic kidney disease dogs were retrospectively included. Serum fibroblast growth factor‐23 concentration and other phosphate metabolite parameters were compared between controls and each International Renal Interest Society stage. Multiple regression analysis was performed to determine the predictors of fibroblast growth factor‐23. Results Serum fibroblast growth factor‐23 concentrations were significantly higher in dogs with IRIS stages 2, 3 and 4 chronic kidney disease than those in dogs in control group and with stage 1 and increased along with the severity of chronic kidney disease. Compared with control dogs, serum intact parathyroid hormone significantly increased from stage 2 and serum phosphorus concentrations increased in dogs with stage 4. In dogs with stage 2, fibroblast growth factor‐23 levels significantly increased in those with hyperphosphatemia compared with those with normophosphatemia. While eight of 26 (30.8%) dogs with stage 2 developed hyperparathyroidism (intact parathyroid hormone>8.5 ng/L), 19 (73.1%) dogs with stage 2 had elevated fibroblast growth factor‐23 levels above the reference range (>528 pg/mL). Log creatinine, log intact parathyroid hormone and log product of total calcium and phosphorus were independent predictors of log fibroblast growth factor‐23. Clinical Significance This preliminary study suggests that canine fibroblast growth factor‐23 might be involved in mineral metabolic disorders associated to chronic kidney disease in dogs, and this factor could be potentially used as an early marker for this condition.